PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Genmab, AbbVie grab priority review for cancer bispecific antibody

Danish biotech Genmab announced this week that the FDA had accepted its Biologics License Application and granted Priority Review for its B-cell lymphoma bispecific antibody, co-developed with AbbVie.

The BLA was supported by the investigational phase 2 EPCORE trial, which evaluated epcoritamab in patients with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin lymphoma (B-NHL). Trial results, shared in June of this year, revealed that the drug demonstrated clinically meaningful efficacy in challenging-to-treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapy.

Epcoritamab is the result of a broad oncology collaboration between Genmab and AbbVie that started in 2020, in which AbbVie paid Genmab $750 million with potential milestone payments totaling 2.15 billion. Since then, the two have partnered to combine Genmab’s DuoBody technology and AbbVie’s payload and ADC technology to select and develop up to four additional differentiated next-generation antibody-based product candidates.

Epcoritamab’s Prescription Drug User Fee Act (PDUFA) date is now May 21, 2023. Roche’s rival immunotherapy, mosunetuzumab, was granted Priority Review back in July and has a decision date of December 29, 2022.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026